Associated Papers
Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.
Mohammad AOA et al.
Cancer Biology & Therapy, 2025
Mutational scanning reveals substrate-assisted autoregulation of the WNT destruction complex.
Padmanarayana M et al.
Biorxiv : the Preprint Server for Biology, 2025
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T et al.
Diagnostics (basel, Switzerland), 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
Benmokhtar S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer.
Niu L et al.
Oncology Letters, 2021
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Newell F et al.
Nature Communications, 2019
A targeted next-generation sequencing assay for the molecular diagnosis of genetic disorders with orodental involvement.
Prasad MK et al.
Journal of Medical Genetics, 2016
Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M et al.
Gastrointestinal Endoscopy, 2016
RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM et al.
Endocrine-related Cancer, 2015
Reporting tumor molecular heterogeneity in histopathological diagnosis.
Mafficini A et al.
Plos One, 2014
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R et al.
Thyroid : Official Journal of the American Thyroid Association, 2013
TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.
Eloy C et al.
Virchows Archiv : an International Journal of Pathology, 2012
Comprehensive mutation analysis in colorectal flat adenomas.
Voorham QJ et al.
Plos One, 2012
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD et al.
Neoplasia (new York, N.y.), 2010
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Halaban R et al.
Pigment Cell & Melanoma Research, 2010
Genotype-phenotype relationships in hepatocellular tumors from mice and man.
Stahl S et al.
Hepatology (baltimore, Md.), 2005
The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S et al.
Cancer Biomarkers : Section a of Disease Markers, 0